Skip to content
Companies

GelMEDIX

Hydrogel-delivered cell therapy for geographic atrophy

Raised to date

$747K

of $2.5M offered across 1 Form D filing

Still open
$1.8M
Investors
5
Last filed
Apr 30, 2026

About

GelMEDIX is a preclinical ophthalmology biotech developing regenerative therapies to restore vision lost to degenerative retinal disease. Its core technology is a proprietary in situ forming, photo-crosslinked hydrogel that acts as an injectable scaffold, protecting cells during injection, localizing them at the target site, and providing a framework for tissue regeneration. The lead program, GMX-101, is a retinal pigment epithelial cell therapy for late-stage Geographic Atrophy. The company was founded out of academic collaboration between Reza Dana of Mass. Eye and Ear and Harvard Medical School and Nasim Annabi of UCLA, and is based in Cambridge, Massachusetts.

An injectable hydrogel scaffold that protects transplanted cells during injection and holds them at the target site, addressing the poor cell survival and localization that limit conventional retinal cell therapy delivery. The same platform supports payloads from small molecules through cell and gene therapies.

Funding

  • EquityFiled Apr 30, 2026Form D/A
    $747K/ $2.5M

Product

GMX-101

Cell therapy

A retinal pigment epithelial (RPE) cell therapy delivered in GelMEDIX's injectable hydrogel scaffold, in preclinical development for late-stage Geographic Atrophy, the leading cause of irreversible blindness in adults over 60.

  • Retinal pigment epithelial cell therapy
  • Delivered via in situ forming injectable hydrogel scaffold
  • Targets late-stage Geographic Atrophy

Built for

Patients with degenerative retinal disease, particularly late-stage Geographic Atrophy, reached through retinal specialists, plus pharmaceutical partners licensing the hydrogel scaffold platform

People on file